DELTA-8 is a pharma-grade cannabinoid product that has been chemically formulated and lab-tested to mimic the natural effects of marijuana. DELTA-8’s formula contains both CBG and CBD which many medical marijuana patients find effective for treating symptoms associated with cancer, AIDS, glaucoma, pain, spasticity, and more.
Besides offering therapeutic benefits, DELTA-8 acts as a sedative and muscle relaxant which makes it perfect for those who struggle with sleeplessness or chronic pain problems. Delta 8 has an analgesic potency approximately 5 times greater than aspirin (please reference lab results below), but does not carry the same gastrointestinal side effects associated with NSAIDs like aspirin.
As a whole plant lipid extract, DELTA-8 contains all the beneficial cannabinoids in their acid forms (CBG and THC-V).
DELTA-8 has been clinically tested by GW Pharmaceuticals and has proven to be effective in treating anxiety and neuropathic pain. It is currently undergoing Phase 2 clinical trials with patients suffering from glioblastoma multiforme (GBM) in Israel. Additionally, two preclinical studies on DELTA-8 were published in Neuropharmacology; one of them is an open-label, add-on study targeting 34 GBM patients. Preliminary results indicate that there was a reduction in tumor size among 20 of the 34 patients enrolled. Of these 20 patients, seven had a partial response, and thirteen had stable disease.
DELTA-8 has also undergone Phase 1 and 2 clinical trials for treating chemotherapy-induced nausea and vomiting (CINV). The results showed that delta 8 online is effective in reducing CINV among cancer patients who participated in the trial.
A preclinical study conducted on rhesus monkeys suggests that DELTA-8 can reduce nociceptive behavior (a painful response to stimuli) without causing motor impairment, one of the side effects associated with opioid pain killers. “Opioid systems are thought to be important targets for the treatment of pain, however they are also linked to drug abuse, constipation, respiratory depression and decreased cognition.”
Results from another preclinical study suggest that DELTA-8 may have antiemetic/anti-nausea properties. The study showed that DELTA-8 was more effective in reducing nausea than the FDA-approved 5-HT3 antagonist’s ondansetron and granisetron.
DELTA-8 is currently being sold in New Zealand, Spain, Switzerland, Israel, and the Netherlands by pharmaceutical companies with plans to sell it in additional countries soon. Additionally, there are drug trials for GBM set to begin next year with hopes of testing the product on other types of cancer in 2016.